Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks the mitochondrial electron transport chain of the malaria parasite, halting ATP production, while proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme. The combined effect stops parasite replication and leads to rapid clearance of the infection.

The dosage of Malarone is determined by the prescribing clinician based on the patient’s age, weight, indication (prevention or treatment), and local resistance patterns. Patients should follow the exact regimen provided by their healthcare provider.

Malarone should be used in pregnancy or while breastfeeding only if the potential benefit outweighs the risk. Healthcare professionals will assess individual circumstances and may recommend alternative prophylaxis or treatment options when appropriate.

To order Malarone, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone offers a convenient once‑daily dosing regimen and combines two mechanisms of action, providing high efficacy against chloroquine‑resistant Plasmodium falciparum. Compared with older agents such as chloroquine or mefloquine, it generally has a more favourable side‑effect profile and lower risk of neuropsychiatric adverse events.

Malarone tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Malarone is taken orally with food or a milky drink to improve absorption. The tablets are swallowed whole with a full glass of water. For prophylaxis, dosing typically starts 1–2 days before travel, continues daily during exposure, and is continued for 7 days after leaving the endemic area.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, significant liver enzyme elevations, hemolysis in patients with G6PD deficiency, and rare cases of anaphylaxis. Patients should seek immediate medical attention if they develop rash, jaundice, dark urine, or signs of an allergic reaction.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil or any component of the formulation, and in patients with severe renal or hepatic impairment where dosing cannot be safely adjusted. It should also be avoided in regions with documented resistance to the drug combination.